The Interrelationship of the Immune Response and Cancer. Proceedings of the Seventh Annual San Francisco Cancer Symposium. Vol. 7 of Frontiers of Radiation Therapy and OncologyThe Interrelationship of the Immune Response and Cancer. Proceedings of the Seventh Annual San Francisco Cancer Symposium. Vol. 7 of Frontiers of Radiation Therapy and Oncology. Ed. by VaethJerome M., M.D. Cloth, $19.50. Pp. 222, with 48 figures and 27 tables. Baltimore, University Park Press, 1972.

Radiology ◽  
1973 ◽  
Vol 108 (1) ◽  
pp. 138-138
Author(s):  
Murray Boles
Keyword(s):  
Immune Response ◽  
Radiation Therapy ◽  
San Francisco

Radiation Therapy in the Treatment of Partially Resected Meningiomas

Neurosurgery ◽  
1987 ◽  
Vol 20 (4) ◽  
pp. 525-528 ◽  
Author(s):  
Nicholas M. Barbaro ◽  
Philip H. Gutin ◽  
Charles B. Wilson ◽  
Glenn E. Sheline ◽  
Edwin B. Boldrey ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
San Francisco ◽  
Tumor Location ◽  
Convincing Evidence ◽  
Subtotal Resection ◽  
Intracranial Meningioma ◽  
Total Resection ◽  
Female Ratio ◽  
Time To Recurrence ◽  
Male Female Ratio

Abstract To address the question of whether radiation therapy is beneficial in the management of partially resected meningiomas, we reviewed the records of all patients admitted to the University of California, San Francisco, between 1968 and 1978 who had a diagnosis of intracranial meningioma. The patients were divided into three groups: 51 patients had gross total resection and did not receive radiation therapy, 30 patients had subtotal resection and no radiation therapy, and 54 patients had subtotal resection followed by radiation therapy. The subtotal resection groups were similar in average age, male: female ratio, and tumor location, which allowed a valid comparison of the effects of irradiation. The recurrence rate in the total resection group was 4% (2 of 51 patients). Among patients in the subtotal resection groups, 60% of nonirradiated patients had a recurrence, compared with only 32% of the irradiated patients. The median time to recurrence was significantly longer in the irradiated group than in the nonirradiated group (125 vs. 66 months, P < 0.05). There was no complication related to irradiation. These results provide convincing evidence that radiation therapy is beneficial in the treatment of partially resected meningiomas.

scholarly journals Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?

2018 ◽  
Vol 19 (12) ◽  
pp. 3793 ◽  
Author(s):  
Mathieu Césaire ◽  
Juliette Thariat ◽  
Serge M. Candéias ◽  
Dinu Stefan ◽  
Yannick Saintigny ◽  
...  
Keyword(s):  
Immune Response ◽  
Radiation Therapy ◽  
T Lymphocytes ◽  
Ionizing Radiation ◽  
Cytotoxic T Lymphocytes ◽  
Tumor Antigens ◽  
Checkpoint Inhibitors ◽  
Parp Inhibitors ◽  
Antitumor Immune Response ◽  
Parp Inhibition

Immunotherapy has revolutionized the practice of oncology, improving survival in certain groups of patients with cancer. Immunotherapy can synergize with radiation therapy, increase locoregional control, and have abscopal effects. Combining it with other treatments, such as targeted therapies, is a promising means of improving the efficacy of immunotherapy. Because the value of immunotherapy is amplified with the expression of tumor antigens, coupling poly(ADP-ribose) polymerase (PARP) inhibitors and immunotherapy might be a promising treatment for cancer. Further, PARP inhibitors (PARPis) are being combined with radiation therapy to inhibit DNA repair functions, thus enhancing the effects of radiation; this association might interact with the antitumor immune response. Cytotoxic T lymphocytes are central to the antitumor immune response. PARP inhibitors and ionizing radiation can enhance the infiltration of cytotoxic T lymphocytes into the tumor bed, but they can also enhance PD-1/PDL-1 expression. Thus, the addition of immune checkpoint inhibitors with PARP inhibitors and/or ionizing radiation could counterbalance such immunosuppressive effects. With the present review article, we proposed to evaluate some of these associated therapies, and we explored the biological mechanisms and medical benefits of the potential combination of radiation therapy, immunotherapy, and PARP inhibitors.

Hafnium Oxide Nanoparticle Activated By Radiation Therapy Generates an Anti-Tumor Immune Response

2018 ◽  
Vol 102 (3) ◽  
pp. S204-S205 ◽  
Author(s):  
J. Galon ◽  
M. Laé ◽  
J.O. Thariat ◽  
S. Carrere ◽  
Z. Papai ◽  
...  
Keyword(s):  
Immune Response ◽  
Radiation Therapy ◽  
Hafnium Oxide ◽  
Oxide Nanoparticle

Current Concepts of Tumor Immunology III. Immune Therapy

1978 ◽  
Vol 87 (1) ◽  
pp. 138-141 ◽  
Author(s):  
Charles J. Krause ◽  
John O. Nysather
Keyword(s):  
Immune Response ◽  
Radiation Therapy ◽  
Tumor Cells ◽  
Tumor Immunology ◽  
Normal Tissue ◽  
Immune Therapy ◽  
Great Promise ◽  
Adjacent Normal Tissue ◽  
Immune Response To Cancer ◽  
Treatment Surgery

It is apparent that development of consistently effective methods of immunotherapy must await a more thorough understanding of the immune response to cancer. However, even those forms of immunotherapy which have been developed to date indicate a tremendous potential. It appears that immunotherapy may be most useful as an adjuvant to established forms of treatment. Surgery, radiation therapy and/or chemotherapy are used to remove all of the gross tumor, with immune therapy then employed to destroy the small foci of tumor which remain. As methods are developed which are effective in counteracting the immunosuppression of tumors, other means of immunotherapy may be found which are capable of destroying tumor cells while not affecting the adjacent normal tissue. Thus, the future of immune therapy holds great promise. As more is learned about the immune response to cancer, advances in therapy will certainly follow.

Sign in / Sign up

Export Citation Format

Share Document